Alfonso G. Zulueta net worth and biography

Alfonso Zulueta Biography and Net Worth

Mr. Alfonso G. Zulueta, also known as Chito, has been a Senior Vice President at Eli Lilly and Company since January 1, 2014 and its President of Lilly International since February 1, 2017 and served as its President of Emerging Markets. Mr. Zulueta served as the President and General Manager at Eli Lilly Japan K.K. from July 1, 2008 to January 1, 2014. Mr. Zulueta served as Area Director of Asia of Eli Lilly & Co. since July 2008. He served as President of Asian Operations of Eli Lilly & Co. since July 2005 and served as its Vice President of US Sales and Marketing of Neuroscience, Family Health and Diabetes since January 2004. As a Lilly employee since 1988, Mr. Zuluetaheld several sales and marketing positions in the United States before he became General Manager for the Philippines in 1995. In 1998, he was named as Director of Marketing for Asia-Pacific and Area Director of Asia-Pacific operations (Singapore) in 1999. In 2001, he became President of Oncology and Critical Care Products. Mr. Zulueta also served as Vice President of Global Marketing, post submission products of Eli Lilly since January 2003. He served as a Member of the senior management forum. He received a 1999/2000 Chairman's Ovation Award, an award presented annually to a small group of exceptional leaders by Lilly Chairman, President and Chief Executive Officer Sidney Taurel. Mr. Zulueta received a Bachelor's degree in Economics from DeSalle University in the Philippines in 1982 and a Master's degree in Business Administration from the University of Virginia in 1987.

What is Alfonso G. Zulueta's net worth?: The estimated net worth of Alfonso G. Zulueta is at least $13.91 million as of July 9th, 2020. Mr. Zulueta owns 18,646 shares of Eli Lilly and Company stock worth more than $13,913,645 as of November 18th. This net worth approximation does not reflect any other investments that Mr. Zulueta may own. Learn More about Alfonso G. Zulueta's net worth.
How do I contact Alfonso G. Zulueta?: The corporate mailing address for Mr. Zulueta and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on Alfonso G. Zulueta's contact information.
Has Alfonso G. Zulueta been buying or selling shares of Eli Lilly and Company?: Alfonso G. Zulueta has not been actively trading shares of Eli Lilly and Company over the course of the past ninety days. Most recently, Alfonso G. Zulueta sold 11,000 shares of the business's stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $170.00, for a transaction totalling $1,870,000.00. Following the completion of the sale, the senior vice president now directly owns 18,646 shares of the company's stock, valued at $3,169,820. Learn More on Alfonso G. Zulueta's trading history.
Who are Eli Lilly and Company's active insiders?: Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), Michael Harrington (VP), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (EVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.
Are insiders buying or selling shares of Eli Lilly and Company?: In the last year, insiders at the sold shares 26 times. They sold a total of 1,410,659 shares worth more than $1,192,819,015.29. The most recent insider tranaction occured on November, 8th when CAO Donald A Zakrowski sold 900 shares worth more than $723,042.00. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.
Information on this page was last updated on 11/8/2024.

Alfonso G. Zulueta Insider Trading History at Eli Lilly and Company

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/9/2020	Sell	11,000	$170.00	$1,870,000.00	18,646
6/16/2020	Sell	17,000	$162.94	$2,769,980.00	39,646
9/20/2019	Sell	4,500	$117.00	$526,500.00	33,806
9/3/2019	Sell	19,500	$112.91	$2,201,745.00	38,306
4/12/2019	Sell	10,000	$124.65	$1,246,500.00	57,806
1/31/2019	Sell	4,000	$120.00	$480,000.00
10/4/2018	Sell	7,000	$114.64	$802,480.00	45,224
9/18/2018	Sell	6,000	$106.31	$637,860.00	55,224
11/10/2017	Sell	2,003	$83.67	$167,591.01	43,580
2/6/2017	Sell	15,000	$77.66	$1,164,900.00	45,583
4/27/2016	Sell	12,000	$76.27	$915,240.00	45,101
1/29/2016	Sell	5,000	$78.75	$393,750.00	57,101

Alfonso G. Zulueta Buying and Selling Activity at Eli Lilly and Company

Eli Lilly and Company Company Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Today's Range

Now: $727.57

$725.01

$731.26

50 Day Range

MA: $882.65

$745.89

$935.09

2 Week Range

Now: $727.57

$561.65

$972.53

Volume

168,391 shs

Average Volume

3,124,822 shs

Market Capitalization

$690.70 billion

P/E Ratio

78.66

Dividend Yield

0.70%

Beta

0.43

❗ RSVP please!

From Behind the Markets | Ad

Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.

Just click here and secure your spot!